Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
A month full of news related to the progress it's making toward helping patients with Duchenne muscular dystrophy (DMD) sparked a 12.9% rally in Sarepta Therapeutics (NASDAQ: SRPT) shares last month, according to S&P Global Market Intelligence.
DMD is a life-shortening, muscle-wasting disease caused by the limited or non-existent production of dystrophin, a protein important to muscle building. DMD is diagnosed in thousands of patients, and there are limited treatment options available.
Sarepta Therapeutics aims to change that.
Source: Fool.com
Sarepta Therapeutics Stock
€130.75
1.870%
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
However, we have a potential of -0.57% for Sarepta Therapeutics as the target price of 130 € is below the current price of 130.75 €.
